Get startedLog in
    Picture of Viracta Therapeutics logo

    VIRX — Viracta Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMicro CapSucker Stock
    All News

    Brief: Viracta Therapeutics Announces Orphan Drug Designation Granted By The US FDA To Nana-Val For The Treatment Of Nasopharyngeal Carcinoma

    Picture of Viracta Therapeutics logoViracta Therapeutics
    12/12/2023 14:11
    Dec 12 (Reuters) - Viracta Therapeutics Inc  VIRX.O :
    * VIRACTA THERAPEUTICS ANNOUNCES ORPHAN DRUG DESIGNATION
GRANTED
BY THE U.S. FDA TO NANA-VAL FOR THE TREATMENT OF NASOPHARYNGEAL
CARCINOMA
    * VIRACTA THERAPEUTICS INC:  ON TRACK TO EXPAND INTO PHASE 2
PORTION OF NANA-VAL IN 2024

Source text for Eikon:  ID:nGNX1V13wY 
Further company coverage:  VIRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Viracta Therapeutics

    See all news